Excellent outcome for pediatric patients with high-risk Hodgkin lymphoma treated with brentuximab vedotin and risk-adapted residual node radiation

ML Metzger, MP Link, AL Billett, J Flerlage… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Brentuximab vedotin, an effective anti-CD30 antibody-drug conjugate approved
for use in adults with classical Hodgkin lymphoma (HL), was introduced in this frontline trial …
被引用次数：42 相关文章

Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation

ML Metzger, MP Link, AL Billett… - Journal of Clinical …, 2021 - ingentaconnect.com
PURPOSE Brentuximab vedotin, an effective anti-CD30 antibody-drug conjugate approved
for use in adults with classical Hodgkin lymphoma (HL), was introduced in this frontline trial …

Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation

ML Metzger, MP Link, AL Billett… - Journal of clinical …, 2021 - pubmed.ncbi.nlm.nih.gov
Purpose Brentuximab vedotin, an effective anti-CD30 antibody-drug conjugate approved for
use in adults with classical Hodgkin lymphoma (HL), was introduced in this frontline trial to …

Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation.

ML Metzger, MP Link, AL Billett, J Flerlage… - Journal of Clinical …, 2021 - europepmc.org
Purpose Brentuximab vedotin, an effective anti-CD30 antibody-drug conjugate approved for
use in adults with classical Hodgkin lymphoma (HL), was introduced in this frontline trial to …
[HTML] nih.gov

[HTML][HTML] Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation

ML Metzger, MP Link, AL Billett, J Flerlage… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Brentuximab vedotin, an effective anti-CD30 antibody-drug conjugate approved
for use in adults with classical Hodgkin lymphoma (HL), was introduced in this frontline trial …